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Introduction
Ineffective erythropoiesis is a distinguishing feature of  β-thalassemias (β-thals), common inherited red cell 
disorders due to the absence of, or the reduction in, synthesis of  β-globin chains (1–6). In β-thal, the excess 
of  unpaired α-globin chains and the decoupling between heme and β-globin chain synthesis with relative free 
heme excess results in enhanced production of  reactive oxygen species (ROS) with severe cellular oxidative 
damage, leading to a block in cell maturation at the basophilic erythroblast stage, increased cell apoptosis, and 
ineffective erythropoiesis. ROS continue to inflict damage on the maturing reticulocytes and erythrocytes, 
causing hemolysis and a dramatically shortened red cell survival in the peripheral circulation (5, 7).
Several mechanisms play a key role in modulating ROS-related cytotoxic effects during erythroid mat-
uration in β-thal (8–11). The heme-regulated eIF2α kinase (HRI) is highly sensitive to intracellular eryth-
roid heme concentrations and is a key heme-sensing regulator of  globin chain production. HRI can also 
be activated by denatured proteins, such as the α-globin aggregates seen in β-thal, and is necessary for the 
cytoplasmic unfolded protein response (9). HRI also regulates responses to increased ROS production. 
Absence of  HRI worsens anemia in a β-thal mouse model (8–11). Peroxiredoxin-2 (Prx2) binds heme 
Anemia of β-thalassemia is caused by ineffective erythropoiesis and reduced red cell survival. 
Several lines of evidence indicate that iron/heme restriction is a potential therapeutic strategy for 
the disease. Glycine is a key initial substrate for heme and globin synthesis. We provide evidence 
that bitopertin, a glycine transport inhibitor administered orally, improves anemia, reduces 
hemolysis, diminishes ineffective erythropoiesis, and increases red cell survival in a mouse model 
of β-thalassemia (Hbbth3/+ mice). Bitopertin ameliorates erythroid oxidant damage, as indicated 
by a reduction in membrane-associated free α-globin chain aggregates, in reactive oxygen species 
cellular content, in membrane-bound hemichromes, and in heme-regulated inhibitor activation and 
eIF2α phosphorylation. The improvement of β-thalassemic ineffective erythropoiesis is associated 
with diminished mTOR activation and Rab5, Lamp1, and p62 accumulation, indicating an improved 
autophagy. Bitopertin also upregulates liver hepcidin and diminishes liver iron overload. The 
hematologic improvements achieved by bitopertin are blunted by the concomitant administration 
of the iron chelator deferiprone, suggesting that an excessive restriction of iron availability might 
negate the beneficial effects of bitopertin. These data provide important and clinically relevant 
insights into glycine restriction and reduced heme synthesis strategies for the treatment of 
β-thalassemia.
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with high affinity and reduces its pro-oxidant effect during erythropoiesis (12–15). Both HRI and Prx2 are 
dynamically modulated in β-thal erythroblasts to favor erythroid survival and maturation (10, 11, 13).
Previous studies have shown that modulation of  heme homeostasis might affect erythropoiesis (16) and 
beneficially affect β-thal erythroid maturation (17). In erythroblasts, glycine uptake via the glycine carrier 
system, GlyT1, is a key determinant of  the rate of  heme biosynthesis and bioavailability (18, 19). Indeed, 
mice genetically lacking GlyT1 display a hypochromic microcytic anemia associated with a 25% reduced 
mean corpuscular hemoglobin (MCH) and mean corpuscular volume (MCV), supporting the importance 
of  GlyT1 in providing glycine for heme biosynthesis during erythroid maturation (16).
Bitopertin is an oral selective inhibitor of  GlyT1 that was originally developed to treat negative symp-
toms of  patients with schizophrenia (20–23). Although efficacy of  bitopertin in schizophrenia could not be 
proved in several randomized, double-blind, placebo-controlled, phase III trials, a dose-dependent micro-
cytic hypochromic erythropoiesis with reduction in hemoglobin (Hb) values was consistently observed in 
bitopertin-treated subjects. This indicated the ability of  bitopertin to inhibit GlyT1-mediated glycine trans-
port during normal erythropoiesis, generating a “heme-restricted” environment (20, 21). Heme-sensing 
HRI has been shown to be responsible for microcytic hypochromic anemia of  iron deficiency (10).
Here, we sought to determine the role of  “heme restriction” on β-thal ineffective erythropoiesis. Our 
goal was to examine whether bitopertin could influence ineffective erythropoiesis and improve red cell 
survival and anemia in an established mouse model for β-thal. We report that treatment of  β-thal mice with 
oral bitopertin reduces ineffective erythropoiesis and ameliorates multiple markers of  oxidant damage, 
resulting in improved red cell survival and reduction of  anemia and hemolysis. Coadministration of  an oral 
iron chelator reduces the beneficial effect of  bitopertin in β-thalassemic mice.
Results
Bitopertin improves anemia of  β-thalassemic mice. In β-thalassemic (B6;129P2-Hbb-b1tm1Unc Hbb-b2tm1Unc/J) hetero-
zygous; Hbbth3/+) mice, oral bitopertin (at the dosage of  30 mg/kg/d, given once daily via gavage) improved 
red cell morphology compared with vehicle-treated animals (Figure 1A). This was associated with increased 
Hb at 2 weeks of  treatment, then with reaching a plateau, which was maintained until the end of  the bitop-
ertin treatment period at day 28 (Figure 1B). A significant increase in Hb was also observed in Hbbth3/+ mice 
treated with bitopertin at lower dosages of  either 3 or 10 mg/kg/d (Supplemental Figure 1A; supplemental 
material available online with this article; https://doi.org/10.1172/jci.insight.130111DS1). In Hbbth3/+ mice 
treated with 30 mg/kg/d bitopertin, the increased Hb values were associated with an increase in RBC counts 
(Supplemental Figure 1B) and a slight but significant decrease in MCV (Supplemental Figure 1B) with a 
slightly increased MCH (Figure 1B, days 7 and 14 only). Significant decreases in absolute reticulocyte counts 
and in circulating erythroblasts were also found in Hbbth3/+ mice treated with bitopertin at dosages of  either 30 
or 10 mg/kg/d for 28 days (Figure 1B and Supplemental Figure 1C). No major change in these parameters 
was observed in Hbbth3/+ mice treated with a lower bitopertin dose of  3 mg/kg/d.
The amelioration of  anemia and red cell indices was associated with a significant reduction in α-globin 
membrane precipitates and an increase in the fraction of  soluble Hb in red cells from bitopertin-treated 
Hbbth3/+ mice compared with vehicle-treated animals (Figure 1, C and D). This was associated with a sig-
nificant decrease in plasma total bilirubin and lactate dehydrogenase, known markers of  hemolysis (Figure 
1E). In agreement with these results, we found a marked reduction in plasma erythropoietin (EPO) in 
bitopertin-treated Hbbth3/+ mice compared with vehicle-treated animals (Supplemental Figure 1D).
Taken together, these results indicate that bitopertin ameliorates anemia of  Hbbth3/+ mice. WT mice 
showed hematologic changes similar to those previously reported in healthy rats, with the appearance of  
mild hypochromic microcytic erythrocytes in the absence of  anemia (20).
Bitopertin reduces β-thalassemic ineffective erythropoiesis. In Hbbth3/+ mice, bitopertin (30 mg/kg/d) significant-
ly decreased extramedullary erythropoiesis as supported by (a) the reduction in the spleen/body weight ratio, 
(b) the decrease of  iron accumulation in the spleen assessed with Pearl’s staining, and (c) the reduction in 
spleen erythropoietic activity and in bone marrow total erythroblasts (Figure 2, A–C, and Supplemental Fig-
ure 2, A and B). This was associated with improvement in morphology of  β-thal erythroblasts, as supported 
by the presence of  more regular nuclear shape, increased nuclear condensation, reduction in the number of  
binucleated cells, and improved enucleation as observed in some orthochromatic erythroblasts (Figure 2D).
Because β-thal is characterized by ineffective erythropoiesis with blockage in erythroid maturation 
associated with expansion of  more immature erythroblasts, we evaluated the ratio between orthochromatic 
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Figure 1. Bitopertin treatment improves chronic hemolytic anemia of a mouse model for β-thalassemia. Data from WT and Hbb3th/+ mice treated with 
either vehicle or bitopertin 30 mg/kg/d are presented. (A) Normal erythrocyte blood smear morphology in bitopertin-treated WT mice. Hbbth3/+ showed 
typical hypochromic red cells, marked polychromasia, and various forms of fragmented erythrocytes (poikilocytes) associated with stressed erythropoiesis 
and hemolysis. Significant improvement of poikilocytosis after 2 and 4 weeks of treatment with bitopertin. May-Grünwald-Giemsa–stained smears were 
imaged under oil at original magnification ×100 using a Panfluor objective with 1.30 numeric aperture on a Nikon Eclipse DS-5M camera and processed 
with Digital Slide (DS-L1) Nikon. One representative image from the other 6 with similar results is presented. (B) Hemoglobin (Hb), mean corpuscular Hb 
(MCH), reticulocyte count, and circulating erythroblasts in WT (n = 6) and Hbb3th/+ mice (n = 6) mice under either vehicle or bitopertin treatment. Data are 
presented as mean ± SD; *P < 0.05 compared with WT mice; °P < 0.05 compared with baseline values; 2-way ANOVA with Tukey’s test for multiple com-
parisons. (C) Upper: Triton acid urea gel electrophoresis of red cell membrane from WT and Hbbth3/+ mice under either vehicle or bitopertin treatment (28 
days). Lower: Quantification of gel bands (OD) expressed as α-globin to β-globin ratio to Hb. Data are shown as median and minimum/maximum (n = 6); 
*P < 0.02 compared with WT animals; °P < 0.05 compared with vehicle-treated Hbbth3/+ mice; 2-way ANOVA with Holm-Šídák test for multiple compar-
isons. (D) Measurement of total and soluble Hb by Drabkin’s method in hemolysates from Hbbth3/+ mice under either vehicle or bitopertin treatment (30 
mg/kg/d, 28 days). Data are shown as mean ± SD (n = 6); *P < 0.05 compared with vehicle-treated Hbbth3/+ mice. °P <0.05 compared with vehicle-treated 
group. (E) Plasma total bilirubin and lactate dehydrogenase in WT (n = 4) and Hbb3th/+ mice (n = 4) mice under either vehicle or bitopertin treatment (30 
mg/kg/d, 28 days). Data are presented as median and minimum/maximum; *P < 0.05 compared with WT mice; °P < 0.05 compared with vehicle-treated 
group; Mann-Whitney U test with multiple-comparisons corrections.
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(more mature) and polychromatic (more immature) erythroblasts, expressed as erythroid maturation index 
(13, 24). In Hbbth3/+ mice, bitopertin treatment (30 mg/kg/d) induced a significant increase in maturing 
erythroblasts in the spleen (Figure 2E) but not in bone marrow (data not shown). To further analyze the 
impact of  bitopertin on β-thal erythropoiesis, we used the CD71-TER119 gating strategy (Supplemental 
Figure 2C). This allowed us to observe a significant reduction in bone marrow basophilic (II) and poly-
chromatic (III) erythroblasts and a marked increase in orthochromatic (IV) erythroblasts in Hbbth3/+ mice 
treated with 30 mg/kg/d bitopertin (Supplemental Figure 2C). A reduction of  all maturating populations 
was observed in the spleen, reflecting an overall decrease in extramedullary erythropoiesis in Hbbth3/+ mice 
treated with 30 mg/kg/d bitopertin (Supplemental Figure 2C).
In the bone marrow from bitopertin-treated Hbbth3/+ mice, a significant decrease in the amount of  
annexin V+ cells present in the CD44loTer119+Fsclo and CD44–Ter119+Fsclo populations was also observed 
(Supplemental Figure 3A).
The bitopertin-induced improvement of  ineffective erythropoiesis and of  its EPO responsiveness was 
supported by upregulation of  cytokine-inducible SH2-containing protein (Cish), a gene strictly dependent 
on STAT5 function, and erythroferrone (Erfe), which is also linked to iron homeostasis (12, 25–27) (Figure 
2F), and by reduction in plasma EPO levels (Supplemental Figure 1D). This was associated with downreg-
ulation of  Nqo1, an antioxidant system (Figure 2F) (12, 25–27). Collectively, our data suggest that heme 
restriction induced by bitopertin ameliorates β-thalassemic ineffective erythropoiesis, improving EPO 
responsiveness and reducing oxidative stress.
Bitopertin reduces liver iron overload and oxidative stress and modulates liver hepcidin expression in a dose-depen-
dent manner. Liver iron overload is a distinguishing feature of  β-thal, a consequence of  ineffective erythro-
poiesis and inappropriate hepcidin (Hamp) downregulation (28–30). In Hbbth3/+ mice, bitopertin treatment 
(30 mg/kg/d) significantly reduced liver iron overload in both hepatocytes and Kupffer cells compared with 
vehicle-treated animals (Figure 3A and Supplemental Figure 3B). A significant reduction in liver protein 
oxidation as assessed by OxyBlot was observed (Figure 3B), in conjunction with reduced activation of  cyto-
protective systems, such as heme oxygenase 1, or Nqo1 and Prx2, 2 potent antioxidant systems (Figure 3C). 
Bitopertin treatment resulted in upregulation of  liver Hamp expression in Hbbth3/+ mice (Figure 3D). This 
was associated with upregulation of  inhibitor of  DNA binding 1 (Id1), which is linked to the activation of  
the SMAD system (Figure 3D). No major change in either STAT3 or ERK1/2 activation was observed in 
bitopertin-treated Hbbth3/+ mice compared with vehicle-treated animals (Supplemental Figure 3C).
To better understand the impact of  bitopertin on Hamp, we administered bitopertin at the lower dose 
of  10 mg/kg/d. In Hbbth3/+ mice, bitopertin treatment (10 mg/kg/d) was associated with amelioration of  
murine β-thal anemia, a reduction in splenic and bone marrow erythropoietic activity (Supplemental Fig-
ure 4, A and B). This was again associated with upregulation of  Erfe in sorted erythroblasts (Supplemental 
Figure 5A). Bitopertin-treated Hbbth3/+ mice at a dose of  10 mg/kg/d exhibited downregulation of  Hamp 
(Supplemental Figure 5B), which was associated with upregulation of  Id1 (Supplemental Figure 5C) and 
Figure 2. Bitopertin reduces β-thalassemic ineffective erythropoiesis. (A) Spleen weight/mouse weight ratio in WT and Hbbth3/+ mice with and without 
bitopertin treatment (30 mg/kg/d, 28 days). Data are presented as median and minimum/maximum (n = 6); *P < 0.05 compared with WT mice; °P < 0.05 
compared with vehicle-treated group; Mann-Whitney U test with multiple-comparisons corrections. (B) Iron staining (Pearl’s Prussian blue) in spleens 
from WT and Hbbth3/+ mice with and without bitopertin treatment (30 mg/kg/d, 28 days). One representative image from the other 6 with similar results is 
presented. Original magnification, ×200. See Supplemental Figure 2A for quantitative results of iron staining on Pearl’s Prussian blue. (C) Flow cytometric 
analysis combining CD44-Ter119 and cell size marker strategy (CD44+Ter119+Fschi) on bone marrow and spleens from WT and Hbbth3/+ mice with and without 
bitopertin treatment (28 days). Data are presented as median and minimum/maximum (n = 3); *P < 0.05 compared with WT mice; °P < 0.05 compared 
with vehicle-treated mice; 2-way ANOVA with Holm-Šídák test for multiple comparisons. (D) Upper: Morphology of sorted erythroid cells from Hbbth3/+ 
mice with and without bitopertin treatment (30 mg/kg/d, 28 days). Cytospins were stained with May-Grünwald-Giemsa. Cells were imaged under oil at 
original magnification ×100 using a Panfluor objective with 1.30 numeric aperture on a Nikon Eclipse DS-5M camera and processed with Digital Slide (DS-
L1) Nikon. We show 1 representative image from a total of 6. Erythroblasts with abnormal nuclear shape and binuclear erythroblasts (white arrowhead) 
from Hbbth3/+ mice evaluated on cytospin stained with May-Grünwald-Giemsa. Lower: Data are presented as median and minimum/maximum (n = 6); °P 
< 0.05 compared with vehicle-treated group; 2-way ANOVA with Holm-Šídák test for multiple comparisons. (E) Box plot showing the ratio between poly-
chromatic/orthochromatic erythroblasts used as a maturation index in spleens analyzed by flow cytometry from Hbbth3/+ mice with and without bitopertin 
treatment (30 mg/kg/d, 28 days). Data are presented as median and minimum/maximum (n = 6); °P < 0.05 compared with standard diet; 2-way ANOVA 
with Holm-Šídák test for multiple comparisons. (F) mRNA expression by real-time reverse transcription PCR (qRT-PCR) of Cish, NAD(P)H quinone-1 (Nqo1), 
and erythroferrone (Erfe; Fam132b normalized on number of sorted cells in each subpopulation) genes on sorted polychromatic erythroblasts (Pop III) and 
orthochromatic erythroblasts (Pop IV) from bone marrow of WT and Hbbth3/+ mice with and without bitopertin treatment (30 mg/kg/d, 28 days). Experi-
ments were performed in triplicate. Data are presented as median and minimum/maximum; °P < 0.05 compared with vehicle; ^P < 0.05 Pop IV vs. Pop III; 
Mann-Whitney U test with multiple-comparison corrections.
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reduction of  activation of  STAT3 and ERK1 compared with vehicle-treated animals (Supplemental Figure 
5, D and E). A significant reduction in liver protein oxidation as assessed by OxyBlot was also observed in 
Bitopertin-treated Hbbth3/+ mice at a dose of  10 mg/kg/d (Supplemental Figure 5F).
Taken together, these data indicate a dose-dependent effect of  bitopertin on Hamp expression, with 
lower doses reducing the activation of  STAT3 and ERK1/2, while higher doses of  bitopertin (30 mg/kg/d) 
most likely affect the intracellular iron-driven regulation of  hepcidin through the activation of  the SMAD 
pathway, independent of  Erfe.
β-Thalassemic mice treated with bitopertin and the iron chelator deferiprone show increased extramedullary eryth-
ropoiesis and worsening of  anemia. In β-thal, iron chelation is part of  the goal of  standard treatment to prevent 
organ damage induced by iron overload related to both chronic transfusion regimen and chronic hemolysis. 
However, the presence of  an iron chelator in conjunction with bitopertin treatment might worsen β-thal-
assemic erythropoiesis because of  an additional reduction in iron availability below the minimal value 
required to ensure erythroid maturation.
β-Thalassemic mice were treated with bitopertin at the dosage of  30 mg/kg/d in combination with 
deferiprone (DFP, 1.25 mg/mL) (28). Casu et al. have previously shown in the same mouse model for β-thal 
that DFP did not affect erythropoiesis (28). As shown in Figure 3E, β-thalassemic mice treated with both 
bitopertin and DFP showed a worsening of  the anemia after an early improvement at 14 days of  therapy, with 
a higher MCV than the bitopertin control. The reduction in the elevated reticulocyte count of  β-thalassemic 
mice treated with bitopertin was abolished in animals treated with both bitopertin and DFP (Figure 3E). In 
addition, we found that the stable and significant reduction in circulating erythroblasts induced by bitopertin 
alone could not be maintained after the first week of  treatment when β-thalassemic mice were treated with 
bitopertin with DFP (Figure 3E). These findings suggest a worsening of  ineffective erythropoiesis in bitoper-
tin with DFP–treated β-thalassemic mice compared with β-thalassemic animals treated with bitopertin alone. 
Indeed, we found no major change in erythropoietic activity in β-thalassemic mice under bitopertin with DFP 
treatment compared with vehicle-treated animals (Supplemental Figure 6, A and B).
In circulating red cells, we confirmed the reduction of  ROS in bitopertin-treated β-thalassemic mice, 
whereas in bitopertin with DFP–treated β-thalassemic animals, the generation of  ROS was similar to 
that observed in vehicle-treated animals (Supplemental Figure 6C). In agreement with these findings, we 
observed no change in the accumulation of  free α-globin chain in red cells from bitopertin with DFP–treat-
ed β-thalassemic animals when compared with vehicle-treated animals (Supplemental Figure 6, D and E) 
or in total bilirubin, an indicator of  chronic hemolysis (Supplemental Figure 6F).
These findings suggest that coadministration of  DFP and bitopertin negates the beneficial effects of  
heme restriction induced by bitopertin alone. Bitopertin did not improve anemia in a pilot study in β-thal-
assemic patients, possibly because of  the concomitant iron chelation therapy (31).
Bitopertin decreases the activity of  the HRI with improvement of  autophagy as a quality control process for Hbbth3/+ 
mouse erythroid cells. To understand the impact of  bitopertin-induced heme restriction on heme-dependent 
regulatory pathways in erythropoiesis (8, 11), we evaluated the heme-dependent changes in the kinase 
activities of  HRI. In the WT mice, treatment with bitopertin resulted in microcytic hypochromic anemia 
(Figure 1B and Supplemental Figure 1, A and B) characteristics of  iron deficiency anemia, which requires 
Figure 3. In β-thalassemic mice, bitopertin reduces liver iron overload and oxidative stress with associated upregulation of hepcidin. (A) Iron staining 
(Pearl’s Prussian blue) in liver from WT and Hbbth3/+ mice with and without bitopertin treatment (28 days). One representative image from the other 3 with 
similar results is presented (quantification of iron staining is shown in Supplemental Figure 2E). Original magnification, ×200. (B) Soluble fractions of liver 
from WT and Hbbth3/+ mice with and without bitopertin treatment (30 mg/kg/d, 28 days). The samples were analyzed on 12% SDS-PAGE and subjected to 
OxyBlot. The carbonylated proteins (1 mg) were detected by treating with 2,4-dinitrophenylhydrazine and blotted with anti-DNP antibody. Quantification 
of band area was performed by densitometry and expressed as percentage of WT (right). The data are presented as median and minimum/maximum 
of at least 5 experiments; *P < 0.05 compared with WT; °P < 0.05 compared with vehicle; 2-way ANOVA with Holm-Šídák test for multiple comparisons. 
(C) Left: Western blot (Wb) analysis with specific antibodies against heme oxygenase (HO-1), NAD(P)H quinone-1 (Nqo1), and peroxiredoxin-2 (Prx2), of 
liver from Hbbth3/+ mice with and without bitopertin treatment (30 mg/kg/d, 28 days). One representative gel from 6 with similar results is presented. 
Right: Densitometric analysis of immunoblots is shown in the box plot. Data are presented as median and minimum/maximum; °P < 0.05 compared with 
vehicle; 2-way ANOVA with Holm-Šídák test for multiple comparisons. DU, densitometric units. (D) mRNA expression by qRT-PCR of hepcidin (Hamp) and 
Id1 genes on liver from WT and Hbbth3/+ mice with and without bitopertin treatment (30 mg/kg/d, 28 days). Experiments were performed in triplicate. Error 
bars represent the SDs, median, and minimum/maximum; *P < 0.05 compared with WT; °P < 0.05 compared with vehicle; 2-way ANOVA with Holm-Šídák 
test for multiple comparisons. (E) Hb, mean cell volume (MCV), reticulocyte count, and circulating erythroblasts in WT Hbb3th/+ mice under either bitopertin 
or bitopertin plus deferiprone (DFP) treatment. Data are presented as mean ± SD; *P < 0.05 compared with bitopertin-treated mice; °P < 0.05 compared 
with baseline values; Wilcoxon’s signed-rank test for multiple comparisons.
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HRI. In addition, HRI was activated with elevated protein expression in the spleen samples of  WT mice 
treated with bitopertin (Supplemental Figure 7A). HRI protein expression was also increased and activated 
with hyperphosphorylation in bitopertin-treated mice as compared with control mice (Supplemental Figure 
7A). These results agree with the decreased heme level in bitopertin-induced heme restriction, which acti-
vates HRI, leading to microcytic hypochromic anemia.
In β-thal mice, HRI is activated by accumulation of  denatured α-globin aggregates and oxidative stress 
from excessive heme (8). Because bitopertin markedly affects extramedullary erythropoiesis, erythro-
blasts from the spleen of  Hbbth3/+ mice treated with bitopertin at the dosage of  10 mg/kg/d were sorted 
for analysis of  HRI activity. As shown in Figure 4A, bitopertin treatment reduced the hyperphosphor-
ylation of  highly activated HRI and the phosphorylation of  eIF2α in sorted splenic erythroblasts from 
β-thal mice. The reduced activity of  HRI is consistent with the improvement of  oxidative stress and the 
reduction in α-globin aggregates in β-thal mice by bitopertin treatment (Figure 1C). Although HRI activ-
ity was reduced upon bitopertin treatment, it was still activated with significant eIF2α phosphorylation 
 (Figure 4A) to inhibit α-globin protein synthesis and oxidative stress.
Recently, we reported a link between heme availability, HRI function, and autophagy during erythro-
poiesis (11). A previous study has shown that the autophagy gatekeeper mTOR is activated in β-thalassemic 
murine erythropoiesis, blocking autophagy with impairment of  the quality control process involved in pro-
duction of  red cells (32). Given that efficient autophagy is required for erythroid maturation, we therefore 
evaluated the expression of  some key proteins of  autophagy in reticulocyte-enriched fractions from both 
mouse strains (33–35). We focused our analysis on Rab5, involved in maturation of  autophagosome and 
recycling endosomes, and on specific markers of  different trafficking compartments such as Lamp1, multive-
sicular bodies/late endosomes, or p62 as autophagy adapter controlling protein turnover. The latter has been 
previously shown to be an indirect marker of  the efficiency of  autophagic flux because p62 levels correlate 
with autophagy-related protein degradation (33, 35–40). In bitopertin-treated Hbbth3/+ mice, we found a reduc-
tion in mTOR complex 1 (mTORC1) activation (Ser2448) (41, 42) compared with vehicle-treated Hbbth3/+ 
mice (Figure 4B). This was associated with a reduction in accumulation of  Rab5, Lamp1, and p62, indicating 
an improvement of  autophagy in bitopertin-treated Hbbth3/+ mice (Figure 4B). Indeed, the improvement in the 
quality control process in the production of  red cells was further supported by the reduction in (a) the amount 
of  hemichromes bound to the red cell membrane (Figure 4C), (b) ROS levels (Figure 4D), (c) free α chains, 
and (d) the expression of  key antioxidant systems such as Prx2 and its related enzyme, thioredoxin-reductase, 
where expression was increased in β-thalassemic red cells (Figure 4E, Supplemental Figure 7, A and B). This 
ends in the amelioration of  red cell survival observed in bitopertin-treated β-thalassemic mice (Figure 4F).
Bitopertin affects in vitro human erythropoiesis. To explore the effect of  bitopertin on human erythropoie-
sis, we tested bitopertin in vitro in CD34+ cells derived from peripheral blood of  β-thalassemic intermedia 
patients and normal controls (3, 4, 43). This culture system recapitulates the ineffective erythropoiesis 
observed in vivo in β-thal by exhibiting increased apoptosis and disturbed maturation (3, 4, 43). Because 
bitopertin targets GlyT1, we evaluated the expression of  this molecule in the early (7 days of  culture) and 
in the late phase (14 days) of  erythropoiesis. As shown in Figure 5A, the expression of  GlyT1 was similar 
in both groups, and it was higher in the early phase of  erythropoiesis.
We then carried out preliminary dose-response studies to identify the concentration of  bitopertin to 
be tested in in vitro human β-thalassemic erythropoiesis. Because the amount of  CD34+ cells derived from 
peripheral blood of  patients with β-thalassemic intermedia is limited, the dose-response experiments were 
carried out only in cells from healthy volunteers. In preliminary experiments, various concentrations, tim-
ing, and frequencies of  addition were tested for bitopertin, which resulted in the selection of  a protocol 
using 10 nM of  bitopertin added at day 7 of  the cell culture, a time at which GlyT1 reaches its peak (Sup-
plemental Figure 8A). It is of  note that an increase of  annexin V+ cells was observed at 14 days of  cell 
culture only in the presence of  100 nM bitopertin in normal erythroid precursors, suggesting a possible cell 
toxicity at this higher dose in this cell system (Supplemental Figure 8B).
The addition of 10 nM bitopertin at day 7 on normal erythropoiesis showed a positive impact on cell viabil-
ity at 14 days of cell culture (Supplemental Figure 8B). In normal erythropoiesis, bitopertin at 10 nM induced a 
significant reduction in basophilic erythroblasts (Int-E) and an increase of orthochromatic erythroblasts (Late-E) 
(see Supplemental Figure 8C for gating strategy). Accordingly, an increase of apoptotic Int-E was noted in early 
erythropoiesis, while a significant reduction in apoptotic cells was observed in Late-E, overall indicating an 
acceleration of erythroid maturation of healthy cells (Supplemental Figure 9, A–D) (4, 44).
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Figure 4. Bitopertin treatment modulates HRI activity and improves autophagy, resulting in optimization of the quality control process with amelio-
ration of red cell survival. (A) Wb analysis of HRI phosphorylation and eIF2αP levels in sorted 1.5 × 106 CD44+Ter119+FSChi spleen cells from Hbbth3/+ mice 
with and without bitopertin treatment (10 mg/kg/d, 28 days) (n = 3). (B) Left: Wb analysis of phospho-mTOR (p-mTOR), mTOR, Rab5, Lamp1, and p62 
in reticulocyte-enriched fractions from WT and Hbbth3/+ mice with and without bitopertin treatment (n = 3; 10 mg/kg/d, 28 days). Catalase was used as 
a protein loading control. Right: Densitometric analyses of the immunoblot bands similar to those shown are presented. Data are shown as median and 
minimum/maximum (n = 4); *P < 0.05 compared with WT; °P < 0.05 compared with vehicle; 2-way ANOVA with Holm-Šídák test for multiple comparisons. 
(C) Hemichromes bound to the membrane in WT and Hbbth3/+ mice with and without bitopertin treatment (n = 3; 10 mg/kg/d, 28 days). Data are shown as 
median and minimum/maximum (n = 4); P < 0.05 compared with WT; °P < 0.05 compared with vehicle; 2-way ANOVA with Holm-Šídák test for multiple 
comparisons. (D) ROS levels in red cells of WT and Hbbth3/+ mice with and without bitopertin treatment (10 mg/kg/d, 28 days). Data are presented as 
median and minimum/maximum (n = 6); *P < 0.05 compared with vehicle-treated Hbbth3/+mice; °P <0.05 compared with vehicle. 2-way ANOVA with Holm-
Šídák test for multiple comparisons. (E) Wb analysis of thioredoxin-reductase (Trx-R) and peroxiredoxin-2 (Prx2) in erythrocytes from WT and Hbbth3/+ mice 
with and without bitopertin treatment (n = 3; 10 mg/kg/d, 28 days). Catalase was used as a protein loading control (see Supplemental Figure 6, A and 
B, for densitometric analyses). (F) Red cell survival of CFSE-labeled red cells from WT and Hbbth3/+ mice with and without bitopertin treatment (n = 3; 10 
mg/kg/d, 40 days). Data are presented as mean ± SD (n = 3) from each group; *P < 0.05 compared with WT; °P < 0.05 compared with vehicle; Wilcoxon’s 
signed-rank test for multiple comparisons.
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Figure 5. Bitopertin beneficially affects in vitro β-thalassemic erythropoiesis, with reduction of protoporphyrin IX, as a marker of heme restriction. (A) 
Cell proliferation of β-thalassemic erythroid precursors derived by in vitro liquid culture of CD34+ cells isolated from peripheral blood of β-thal subjects with 
or without bitopertin 10 nM (n = 3). Arrows indicate when bitopertin 10 nM was added to the culture medium (see Supplemental Figure 6B for dose-re-
sponse data on cell viability in normal erythropoiesis). Data are presented as mean ± SD; *P < 0.05 compared with vehicle-treated β-thal cells; Wilcoxon’s 
signed-rank test for multiple comparisons. (B) Effect of bitopertin (10 nM) on maturation pattern of β-thalassemic erythroid precursors from a single 
patient in triplicate. Representative flow cytometric plot and box plots of the differentiation pattern of β-thalassemic erythroid precursors at 14 days of 
culture with or without bitopertin (10 nM). The following surface markers were used: CD36, glycophorin-A, and CD71. This allows for the identification of 
the following homogenous cell populations: pro-erythroblasts (Pro-E), basophilic erythroblasts corresponding to intermediate erythroblasts (Int-E), and 
polychromatic and orthochromatic erythroblasts as late erythroblasts (Late-E) (see also refs. 4, 44). Data are shown as median and minimum/maximum 
(n = 4); *P < 0.05 compared with vehicle-treated β-thalassemic cells; Wilcoxon’s signed-rank test for multiple comparisons. (C) Effect of bitopertin on the 
index of erythroid maturation of β-thalassemic cells from 4 separate individuals at 9 and 14 days of cell culture. *P < 0.05 compared with vehicle-treated 
β-thalassemic cells; Mann-Whitney U test with multiple-comparisons correction. (D) Effect of bitopertin (10 nM) on the amount of annexin V+ cells during 
β-thalassemic erythroid maturation from 4 separate individuals at 9 and 14 days of cell culture. *P < 0.05 compared with vehicle-treated β-thalassemic 
cells, Mann-Whitney U test with multiple-comparison correction. (E) Intracellular content of protoporphyrin IX in healthy and β-thalassemic cells (4.5 × 106 
cells) after 14 days of cell cultures with and without bitopertin (10 nM). Data are presented as median and minimum/maximum (n = 4) from each group; *P 
< 0.05 compared with vehicle; Mann-Whitney U test with multiple-comparisons correction.
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In β-thalassemic erythropoiesis, bitopertin at 10 nM induced a significant increase in cell viability 
compared with vehicle-treated cells (Figure 5A). This was associated with a marked decrease of  baso-
philic erythroblasts (Int-E) and an increase of  orthochromatic erythroblasts (Late-E) compared with 
vehicle-treated β-thalassemic cells (Figure 5, B and C). The improvement of  β-thalassemic erythropoi-
esis was also supported by the significant reduction in the amounts of  annexin V+ cells in both early 
(CFU-E and pro-erythroblasts at 9 days) and late (orthochromatic erythroblasts at 14 days) phases of  
erythropoiesis (Figure 5D).
These data indicate that bitopertin, by promoting heme restriction, ameliorates human β-thalassemic 
erythropoiesis, accelerates erythroid maturation, and reduces cell apoptosis. The presence of  a heme 
restriction state is supported by a reduction in protoporphyrin IX, a heme precursor, in bitopertin β-thal-
assemic erythroid cells (Figure 5E).
Discussion
Ineffective erythropoiesis and reduced red cell survival are the main determinants of  the anemia of  β-thal. 
Oxidant damage due to aggregated free α chain deposition on the cell membrane and to free heme is the 
main driver of  the pathophysiology of  the disease. A variety of  strategies aimed at reducing oxidant dam-
age or improving ineffective erythropoiesis have been considered, and a novel in silico model has been 
developed to test these interventions (45). A possible therapeutic approach is based on restriction of  iron 
availability to reduced heme and free iron–induced oxidant damage. We have explored in this work the role 
of  restricting the cellular supply of  glycine with the use of  bitopertin, an inhibitor of  the GlyT1 transporter, 
because glycine is a key element for both heme synthesis and globin protein production.
In a mouse model of  β-thal intermedia, we report here that the GlyT1 inhibitor, bitopertin, substan-
tially improves anemia with a marked reduction in splenic erythropoiesis. In mice, splenic erythroid 
activity is rapidly activated in response to stress or in pathologic erythropoiesis (1, 46). Thus, we were not 
surprised to observe the reduction of  spleen erythropoiesis with the improvement of  ineffective erythro-
poiesis. Similar data were also observed in the same mouse model for β-thal treated with activin ligand 
trap RAP-011 (24). As summarized in Figure 6, bitopertin treatment significantly reduces β-thalassemic 
ineffective erythropoiesis accompanied by a reduction in heme level, based on a reduction of  the heme 
precursor protoporphyrin IX free α-globin aggregates, and oxidative stress, as well as the improvement 
of  autophagy-based quality control processes. The reduction of  heme levels upon bitopertin treatment 
is corroborated with the activation of  HRI and the development of  microcytic, hypochromic anemia in 
WT mice. HRI is responsible for microcytic and hypochromic hallmarks of  iron deficiency anemia in 
iron and heme deficiency (10, 47). The beneficial effect of  heme restriction upon bitopertin treatment in 
β-thal is most likely mediated by HRI. HRI is necessary to reduce phenotypic severity of  β-thal, includ-
ing proteotoxicity of  α-globin inclusions, ineffective erythropoiesis, and iron overload (47). However, 
activation of  HRI alone in heme sufficiency cannot mitigate entirely the symptoms of  β-thal. Reduction 
of  heme by bitopertin provides an additional means of  reducing oxidative stress. In heme deficiency, 
HRI inhibits not only globin protein synthesis but also heme biosynthesis as demonstrated in ferroche-
latase-deficient mice (47). Furthermore, HRI is activated and induces activating transcription factor 4 
(ATF4) mRNA translation in mouse β-thalassemic erythroid precursors (47, 48). Activation of  ATF4 
by HRI is necessary to mitigate oxidative stress in iron deficiency, which leads to heme deficiency (11). 
Recent global assessment of  gene expression in erythroblasts demonstrates that HRI and heme-mediated 
translation and subsequent transcriptome changes are most highly activated during iron/heme deficiency 
(49). The increased mTORC1 activity in β-thal mice is most likely due to an elevated EPO level in the 
presence of  anemia. HRI is necessary to repress EPO/mTORC1 signaling as a feedback mechanism for 
EPO-stimulated erythropoiesis in iron deficiency to prevent ineffective erythropoiesis (11), which also 
occurs in β-thal. Repression of  mTORC1 by HRI can also mitigate autophages.
Heme plays a key role in normal erythropoiesis and in the alterations observed in β-thal erythropoi-
esis (3, 5, 17). We and others have shown biphasic behavior in heme biosynthesis, characterized by heme 
accumulation in the early phase of  β-thal erythropoiesis, followed by a relative heme reduction in the late 
phase of  β-thal erythropoiesis (3). Thus, the pool of  “uncommitted heme” in erythroblasts during β-thal 
erythropoiesis is not fixed but varies dynamically according to the development state of  erythroblasts (3, 5, 
17). In erythroblasts treated with bitopertin, the reduction of  protoporphyrin IX associated with increased 
Hb supports the importance of  heme restriction to optimize cell hemoglobinization (Figure 5E).
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The data in β-thal mouse treated with low (3–10 mg/kg/d) and high (30 mg/kg/d) dosages of  bitop-
ertin provide some insights into how higher dosages affect the iron regulatory system and possibly help in 
preventing excessive iron restriction.
A general concern regarding the use of iron restriction as a therapeutic strategy for β-thal is the establishment 
of safe dose ranges and conditions, to prevent an excessive restriction of iron, which will negate the original ther-
apeutic benefits. Similar experiences have been reported in β-thalassemic mice treated with either mini-hepcidin 
or apo-transferrin or with molecules interfering with Tmprss6 function (6, 28, 50–53). A “sweet spot” seems to 
exist between iron restriction and iron deficiency induced by one of the abovementioned treatments, and a devi-
ation from this optimal point may negate the amelioration of β-thalassemic erythropathology by superimposing 
a clinically significant iron-restricted/iron-deficient erythropoiesis. Our in vitro data with CD34+ erythroid pre-
cursors from patients with β-thal do not allow us to establish dose ranges for the human studies, with cellular tox-
icity being observed with 100 nM bitopertin (Supplemental Figure 7B), but show similar reduction in ineffective 
erythropoiesis markers to the one observed in the Hbbth3/+ mouse model with a dose of 10 nM, suggesting that 
the experimental data of the mouse model can be extrapolated to humans.
Because iron chelation is currently indicated for all β-thal syndromes requiring therapeutic interven-
tion, we examined in the Hbbth3/+ mice the effects of  bitopertin treatment in conjunction with the iron 
chelator DFP. Prior work by Casu et al. showed no deleterious effect of  DFP administration to Hbbth3/+ 
Figure 6. Schematic diagram of the downstream effects on β-thalassemic erythroblasts when glycine uptake is impaired by bitopertin, a specific 
inhibitor of the GlyT1 transporter. Bitopertin modulates heme biosynthesis, which affects the amount of free heme (in the in vitro model of human 
erythropoiesis, we observed a reduction of protoporphyrin IX). This results in reduction of oxidative stress with associated decrease in activation of HRI, 
which orchestrates eIF2α and senses free heme concentration. The optimization between heme and α-globin chain synthesis further contributes to the 
reduction in generation of ROS, resulting in the blockage of mTOR and activation of autophagy, which contributes to the clearance of damaged proteins, 
assisting β-thalassemic cell survival during growth and maturation.
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mice (28). Our data indicate that concomitant iron chelation with DFP in the Hbbth3/+ mice severely blunts 
or negates the therapeutic benefits of  bitopertin (Figure 3). Worsening anemia and microcytosis in Hbbth3/+ 
mice treated with both bitopertin and DFP may indicate an unacceptably high level of  iron restriction, 
negatively affecting β-thal erythropoiesis.
Preliminary findings of  a phase II trial of  bitopertin in patients with transfusion-dependent β-thal have 
been recently reported in an abstract (31). With the dosages used in this study, a reduction in Hb and MCH 
were noted with no improvement in hemolysis. The study tested a dose escalation protocol (30 to 60 to 90 
mg/d) for a treatment duration of  16 weeks, and it may be postulated that the concomitant iron chelation 
therapy could have affected the hematologic response, as we have shown for a β-thalassemic mouse model.
In conclusion, we show that bitopertin-induced inhibition of  the GlyT1 transporter beneficially affects 
β-thal ineffective erythropoiesis and improves anemia, hemolysis, and red cell survival in Hbbth3/+ mice. 
Multiple markers in different tissues indicated reduced oxidant damage, reduced liver and spleen iron over-
load, and improved autophagy assisting erythroid maturation. The ineffective erythropoiesis observed with 
in vitro culture of  human β-thal precursor shows similar improvement with bitopertin exposure, indicating 
the translatability of  effects on erythropoiesis between a mouse model and humans.
Methods
Mouse strains and design of  the study. Female 2-month-old WT (C57BL/6) and Hbbth3/+ mice (from established 
mouse colony in CIRSAL, University of  Verona) were studied. In mouse strains, hematologic parameters, 
red cell indices, and reticulocyte count were evaluated at baseline and at different time points as previously 
reported (15, 54). Blood was collected with retroorbital venipuncture in anesthetized mice using heparin-
ized microcapillary tubes. Hematologic parameters were evaluated on a Siemens ADVIA 2120 hematology 
analyzer. Hematocrit and Hb were manually determined (4, 55). We determined α-globin membrane aggre-
gates and soluble Hb as described by Dussit et al. (24). Determining the amount of  hemichromes bound to 
the red cell membrane was carried out as previously reported (15, 56).
Flow cytometric analysis of  mouse erythroid precursors and molecular analysis of  sorted erythroid cells. Flow cyto-
metric analysis of  erythroid precursors from bone marrow and spleen from WT and Hbbth3/+ mice was carried 
out as previously described using the CD44-Ter119 or CD71-Ter119 strategy (1, 12, 57). Analysis of  apop-
totic basophilic, polychromatic, and orthochromatic erythroblasts was carried out on the CD44-Ter119 gated 
cells using the Annexin V PE Apoptosis Detection Kit (eBioscience), following the manufacturer’s instruc-
tions. Erythroblasts’ ROS values were measured as previously reported by Matte et al. (12). Sorted cells were 
used for (a) morphologic analysis of  erythroid precursors on cytospin preparations stained with May-Grün-
wald-Giemsa, (b) qRT-PCR analysis, and (c) immunoblot analysis. Details of  qRT-PCR protocol and immu-
noblot used for the analysis of  sorted erythroblasts and red cells are described in Supplemental Methods.
HRI assay. HRI assay was carried out as previously reported on sorted erythroblasts from the spleen of  
Hbbth3/+ mice treated with either vehicle or bitopertin (11).
Red cell survival. Red cells from WT and β-thal mice treated with or without bitopertin were labeled with 
CFSE (10 μM; Molecular Probes, Invitrogen, Thermo Fisher Scientific) in PBS, with 0.5% BSA, for 20 
minutes at 37°C as previously reported (13).
Pearl’s analysis of  liver and spleen. Immediately following dissection, the spleen and liver were forma-
lin-fixed and paraffin-embedded for Pearl’s staining (12).
Molecular analysis of  liver. Protocols used for RNA isolation, cDNA preparation, and qRT-PCR 
have been previously described (58). Detailed primer sequences are available on request and shown 
in Supplemental Table 1. Liver immunoblot analysis was performed as previously described (12, 59). 
Oxidized proteins were monitored using OxyBlot Protein Oxidation Detection Kit (MilliporeSigma) 
as previously reported (12).
Studies on in vitro human erythropoiesis. We analyzed 10 erythroid cultures obtained from the peripheral 
blood of  different normal subjects and 10 erythroid cultures obtained from 4 patients with homozygous 
β-thalassemic intermedia (β0cod39) (4). The erythroid cell antigen profiling and the sorting of  erythroid pre-
cursors were carried out as previously described (4). Immunoblot analysis of  human erythroid precursors 
was carried out using 1 × 106 cells at 7 and 14 days of  culture from both normal and β-thalassemic subjects, 
which were solubilized as previously described (4). Determination of  protophorphyrin IX was carried out 
on cells from healthy donors in the presence and the absence of  bitopertin. Details are reported in Supple-
mental Methods (60–64).
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Statistics. Data were analyzed using 2-way ANOVA for repeated measures between the mice of various gen-
otypes as well as between healthy and thalassemic cells. A difference with P < 0.05 was considered significant.
Study approval. The Institutional Animal Experimental Committee of  University of  Verona and the 
Italian Ministry of  Health (Rome, Italy) approved the experimental protocols. Informed consent for the use 
of  their blood samples was obtained from healthy subjects and patients.
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